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Pernicious anaemia (PA) is an autoimmune condition where antibodies target intrinsic factor and parietal cells, reducing
the patient’s ability to absorb cobalamin promoting atrophic gastritis. Treatment guidelines are based on excretion data of
hydroxocobalamin from healthy individuals obtained 50 years ago. This manuscript describes the use of phorbol 12-myristate 13-
acetate (PMA) to stimulate low grade inflammation in an epithelial colorectal cell line to assess the efficacy of methylcobalamin
and hydroxocobalamin. Nitric oxide increased significantly in cells exposed to higher doses of PMA (100 ng/ml, 150 ng/ml, and
200 ng/ml) accompanied by a loss of the characteristic cobblestone morphology with no negative effect on cell activity or viability.
A significant reduction in nitric oxide production was associated with the addition of 200 pg/ml hydroxocobalamin, alongside a
return to the characteristic cobblestone morphology. This study highlights the use of PMA to promote low grade inflammation
in human cell lines to model gastric inflammation associated with autoimmunity; furthermore it raises questions regarding the
concentration of cobalamin administered clinically to restore cell functionality, feasibly allowing the patient to receive reduced
quantity of the vitamin more regularly, providing the patient with levels which are akin to dietary intake.
1. Introduction
Patients with inflammatory bowel conditions often suffer
from cobalamin deficiency [1]. It can also lead to pernicious
anaemia (PA) an autoimmune condition associated with
atrophic gastritis resulting in further gastric inflammation.
In atrophic gastritis the parietal cells [2] are destroyed by
autoantibodies towards the H+K+-ATPase on the surface of
the cell [3]. This destruction leads to the decreased secretion
of intrinsic factor (IF), a glycoprotein [4] essential for the
absorption of cobalamin [5]. Oral B12 has been trialled;
however only 8% of UK patients surveyed were on oral
or sublingual medication [6]. Intramuscular injection is the
most frequently administered form of treatment. Untreated
cobalamin deficiency causes psychological symptoms such as
depression, anxiety, and Alzheimer’s disease. Subacute cere-
bral degeneration is a severe but frequently seen symptom
which presents as general weakness, paraesthesia, abnormal
gait, stiffness, and limb weakness [7].
Cobalamin is an essential water soluble vitamin [8]
required as a coenzyme for methionine synthase andmethyl-
malonyl-CoA mutase [4], in the methylation of DNA and
the Krebs cycle, respectively. Cobalamin is an organometallic
compound with a corrin ring structure surrounding a cobalt
molecule [9]. It cannot be synthesized by the body and must
be taken in through the diet. Cobalamin exists in four forms:
hydroxocobalamin, methylcobalamin, cyanocobalamin, and
adenosylcobalamin. Methylcobalamin and adenosylcobal-
amin are biologically active forms of cobalamin [10] whereas
hydroxocobalamin and cyanocobalamin are inactive. In pre-
vious studies the active forms of cobalamin were found
to be protective against cell death induced by increased
homocysteine [11]. Elevated homocysteine levels have been
previously linked with an increased risk ofmyocardial infarc-
tion and Alzheimer’s disease. Methylcobalamin, acting as a
coenzyme with methionine synthase, converts homocysteine
to methionine. Therefore it is not surprising that 98% of
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patients with cobalamin deficiency have an increased total
homocysteine level [12].
The recommended treatment for cobalamin deficiency
is injections of cobalamin. In the UK patients receive sub-
cutaneous injections of hydroxocobalamin every 12 weeks
[6]; however 64% of participants of a survey by the PA
Society (UK) were unhappy with their treatment [6] due to
symptom recurrence before their next injection. It is essential
that patients receive effective and appropriate treatment for
the rest of their lives to ensure a good a quality of life.
The current BNF treatment regime in the UK was based
on a 1968 paper [7] which studied cobalamin excretion.
They found the inactive hydroxocobalamin was retained
for longer in the body than the active cyanocobalamin.
However, the paper cohort was small, 13 in total, and none
of the participants were diagnosed with PA, B12 deficiency,
or associated transport problems. To our knowledge, no
further research has been undertaken in subjects with PA or
associated gastritis to understand the impact of the disease on
cobalamin excretion or more importantly its direct cellular
effect.
Nitric oxide (NO) has been implicated in gastric inflam-
mation, along with NO synthase (NOS). These have been
shown to contribute to the pathology of inflammation by
causing cell cytotoxicity [13]. Cobalamin has been shown to
reduce the bioactivity of NO, as NO will bind to the corrin
ring structure of cobalamin [14]. A 2009 study found that
hydroxocobalamin was the most effective form of cobalamin
in inhibiting NOS [14].
Caco-2 cells are a human colon adenocarcinoma cell
line that has been used to model the gastric epithelium for
almost 30 years [15]. In vitro models using Caco-2 cells to
mimic gastric inflammation [16] in coeliac disease found
that a combination of phorbol myristate acetate (PMA) and
IFN-𝛾 was the best inducer of NO production and therefore
inflammation. Another study found that PMA alone was
sufficient to induce inflammation in Caco-2 cells though at
a lower level compared to IFN-𝛾 [15]. In this experimental
model inflammation will be induced using PMA alone to
mimic a low level of acute gastric inflammation.
The aim of this study is to develop an in vitro model
capable of mimicking low grade gastric inflammation and to
use this model to investigate the activity of clinically relevant
levels of cobalamin as defined by earlier studies and finally
to enhance our current understanding between the impact of
active and inactive cobalamin in the developed gastric model
of inflammation.
2. Materials and Methods
2.1. Gastric Inflammation Study. Caco-2 cells were subcul-
tured at a subcultivation ratio of 1 : 5 in DMEM 10% FBS
(37∘C, 95%O
2
, 5%CO
2
); 1× 105 cellswere seeded in to 24-well
plates and allowed to adhere for 24 hours. Cells were spiked
with phorbol 12-myristate 13-acetate (PMA) (0, 50, 100, 150,
and 200 ng/ml) and incubated for 24 and 48 hours. After
incubation media were removed and centrifuged, processed
for the Griess assay and MTT assays, respectively.
Table 1: Cobalamin concentration and the clinical relevance.
Cobalamin concentration (pg/ml) Clinical relevance of value
0 Control value
200 UK minimum of normalrange [21]
500 Asian minimum of normalrange [22]
750 Midrange of referencerange
1000 UK maximum of normalrange [21]
5000
Five times greater than
maximum range to test for
toxicity of extremes
2.1.1. NO Production. Griess assay (Promega, UK): sul-
fanilamide solution was added to 50𝜇l of each sample
and incubated in the dark prior to the addition of N-
(1-naphthyl)ethylenediamine dihydrochloride (NED). After
incubation the absorbance was read at 520 nm. The limit of
detection is 2.5 𝜇M (125 pmol) nitrite.
2.1.2. Cell Activity. MTT (Sigma-Aldrich, UK) was added
to the remaining wells and incubated; formazan crystal in
wells was dissolved using MTT solubilization solution and
the absorbance measured at 570 nm.
2.1.3. Cell Viability and Morphology. 5-Chloromethylflu-
orescein diacetate in DMSO (10 𝜇M) (Sigma) was added to
wells and incubated with media (DMEM + 10% FBS) prior to
fixing in formalin (3.7%) and observing under the confocal
microscope (Leica, UK).
2.2. Active Cobalamin Toxicity Study. Caco-2 cells were
seeded at 1 × 105 and allowed to adhere for 24 hours.
Cells were spiked with methylcobalamin at clinically relevant
concentrations (Table 1) and incubated for 24 hours. Super-
natant and cells were processed as above for NO production
(Section 2.1.1) and cell viability using MTT (Section 2.1.2).
2.3. In Vitro Model Study. Caco-2 cells were seeded (1 × 105)
to 24-well plates and allowed to adhere for 24 hours inDMEM
10% FBS (37∘C, 95%O
2
, and 5%CO
2
). Cells were spiked with
150 ng/ml phorbol-12-myristate 13-acetate and methylcobal-
amin (0, 200, 500, 750, and 1000 pg/ml) or hydroxocobalamin
(0, 200, 500, 750, and 1000 pg/ml) and incubated for 24 hours
at 37∘C, 5% CO
2
. Supernatants and cells were processed for
NO production using the Griess assay (Section 2.1.1) and cell
viability via MTT assay (Section 2.1.2). Cell morphology was
observed using phalloidin and rhodamine staining; the cells
were fixed in 3.7% formalin prior to washing in sterile PBS
and incubation in phalloidin rhodamine; after incubation the
dye was removed and the samples were viewed under the
confocal microscope.
2.4. Statistics. All statistical information was determined
using one-way ANOVA and Tukey’s method and 95% con-
fidence intervals using Minitab Statistical software.
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Figure 1: Nitric oxide production from colorectal adenocarcinoma
(Caco-2) cells after 24-hour culture with phorbol 12-myristate 13-
acetate (PMA).
3. Results
3.1. Gastric Inflammation Study
3.1.1. Nitric Oxide Production. Caco-2 cells incubated with
PMA showed a positive significant increase in cell production
of nitric oxide with 100, 150, and 200 ng/ml compared to cells
incubated with 0 and 50 ng/ml PMA (𝑝 = 0.0038) (Figure 1).
3.1.2. Cell Activity. Cells incubated with PMA for 24 and 48
hours showed an increase in cell activity. Cells incubated
for 24 hours demonstrated a significant increase in cell
activity from 100 ng/ml reaching a peak at 150 and 200 ng/ml,
where the absorbance for cell activity was significantly greater
than at 0, 50, and 100 ng/ml (𝑝 = 0.0013). Cells at 48
hours demonstrated the greatest activity; indeed there was a
significant increase in cell activity of all cells incubated for 48
hours (𝑝 = 0.7840); however the activity had plateaued and
increasing the concentration of PMA did not influence cell
activity (Figure 2).
3.1.3. Cell Viability and Morphology. Morphological changes
were observed between the control cells incubated without
PMA and those incubated with 150 ng/ml of PMA and
above over 24 hours. Control Caco-2 cells demonstrated
a typical cobblestone morphology (Figure 3(a)), where the
cells were of a similar size with an ovular shaped nucleus.
In contrast, cells with 150 ng/ml PMA displayed an altered
morphological appearance; the cells are clustered but have
lost the stereotypical cobblestone morphology and regular
nucleus, and rather the cells show a more atypical nucleus
(Figure 3(b) white arrows) with identifiable filopodia and
extrusions (data not shown).
3.2. Active Cobalamin Toxicity Study
3.2.1. NO Production. Cells incubated methylcobalamin
demonstrated no significant changes inNO release compared
to controls, and levels of the active cobalamin which reached
a fivefold excess of clinical standards showed no significant
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Figure 2:Cellmetabolic activity asmeasured byMTTassay after 24-
hour and 48-hour incubation in culture with phorbol 12-myristate
13-acetate (PMA) (∗significantly increased (𝑝 = 0.0013)).
difference in the level of NO production (𝑝 = 0.1472)
(Figure 4(a)).
3.2.2. Cell Activity. There was no significant statistical dif-
ference in Caco-2 cell activity after 24-hour incubation with
different concentrations of methylcobalamin (𝑝 = 0.3118)
(Figure 4(b)) (𝑝 = 0.3118).
3.3. In Vitro Model Study
3.3.1. Methylcobalamin. There is a significant increase in
cell activity with 750 pg/ml of methylcobalamin with PMA
compared to all other concentrations of methylcobalamin
(𝑝 = 0.0061) (Figure 5(a)). There is no significant statistical
difference in NO production between cells with and without
PMA at the same concentrations of methylcobalamin (Fig-
ure 5(b)) (𝑝 = 0.1839). The morphology of the cell (Figure 6)
shows distinct changes from cells incubated with the addition
ofmethylcobalamin.When incubated with the lowest clinical
value of methylcobalamin 200 pg/ml (Figure 6(c)) the cells
are elongated rather than cobblestone; they have a reduced
cytoplasm and a rougher cell surface and they appear to
have lost their ability to form a monolayer in comparison
to the control Caco-2 cells (Figure 6(a)). Indeed, their
overall appearance looks similar to that of the cells in the
PMA control (Figure 6(b)) where the rougher cell surface
is also associated with a change of the shape of the nucleus
and a tendency towards more spiked cell morphology. The
cells incubated with the highest dose of methylcobalamin
1000 pg/ml showed a mixed cell population where those on
the tissue culture plastic demonstrated a flattermore rounded
morphology, with a large round nucleus and a cytoplasm
ratio akin to that of the cell control (Figure 6(a)) but these
unlike the cell control were covered with a number of cells
more representative of the PMA control with amore irregular
nucleus and a reduction in cytoplasm (Figure 6(b)).
3.3.2. Hydroxocobalamin. No significant difference was
observed in cell activity with PMA (𝑝 = 0.1941) (Figure 7(a)).
However, NO production was significantly reduced with
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(a) (b)
Figure 3: Colorectal adenocarcinoma (Caco-2) cells after 24-hour incubation with (a) cell culture medium and (b) cell culture medium
spiked with 150 ng/ml phorbol 12-myristate 13-acetate (PMA). White arrows highlight nuclear changes.
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Figure 4: Colorectal adenocarcinoma (Caco-2) cells after 24-hour culture with methylcobalamin (0, 200, 500, 750, 1000, and 5000 pg⋅ml).
(a) Nitric oxide production; (b) cell activity as measured by MTT.
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Figure 5: Colorectal adenocarcinoma (Caco-2) cells after 24-hour culture with 150 ng/ml phorbol 12-myristate 13-acetate (PMA) and
methylcobalamin (0, 200, 500, 750, and 1000 pg/ml). (a) Cell activity as measured by MTT; (b) nitric oxide production (∗significantly
increased 𝑝 = 0.0061).
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Figure 6: Colorectal adenocarcinoma (Caco-2) cells after 24-hour culture with (a) 150 ng/ml phorbol 12-myristate 13-acetate (PMA) (b) and
200 pg/ml methylcobalamin (c) or 1000 pg/ml methylcobalamin (d).
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Figure 7: Colorectal adenocarcinoma (Caco-2) cells after 24-hour culture with 150 ng/ml phorbol 12-myristate 13-acetate (PMA) and
hydroxocobalamin (0, 200, 500, 750, and 1000 pg/ml): (a) cell activity as measured by MTT; (b) nitric oxide production.
the addition of 200 pg/ml hydroxocobalamin (Figure 7(b))
(𝑝 = 0.0008). Imaging of cell morphology highlighted a
clear morphological change in Caco-2 cells incubated with
PMA and hydroxocobalamin (Figure 8). As described cells
incubated with PMA demonstrate an irregular nucleus and
a lack of typical cobblestone morphology (Figure 8(b)),
displaying filopodia extensions. Cells incubated with
150 ng/ml hydroxocobalamin start to demonstrate features of
both populations with cells demonstrating regular nuclei and
fewer projections (Figure 8(c)). Cells further resemble the
controls cells when exposed to 1000 pg/ml hydroxocobalamin
(Figure 8(d)), the cell shape and size having become regular;
however the cells have not yet formed clear clusters seen in
control cells (Figure 8(a)).
4. Discussion
For this study, PMA was used as the inducer of inflamma-
tion as described by Chen and Kitts [15]. PMA activates
protein kinase C (PKC) in epithelial cells [17] by mimicking
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Figure 8: Colorectal adenocarcinoma (Caco-2) cells after 24-hour culture with (a) 150 ng/ml phorbol 12-myristate 13-acetate (PMA) (b) and
150 pg/ml hydroxocobalamin (c) or 1000 pg/ml hydroxocobalamin (d).
diacylglycerol, a natural ligand to PKC. It has been used to
promote inflammation both in vitro [15, 16, 18] and in vivo
[19]. 200mg/ml PMA showed the greatest increase in NO
production (Figure 1) along with the greatest increase in cell
activity (Figure 2). However, a distinct increase in both cell
activity and NO production was seen from concentrations
as low as 100 ng/ml of PMA. Cell morphology showed clear
alterations from the formation of cell clusters with a smooth
cobblestone appearance to rougher surface morphology
where the individual cell nucleus was larger and the cells were
less uniform with the addition of PMA (Figure 3). Similar
morphological changes have been observed in other studies,
where cells incubated with PMA and IFN-𝛾 showed changes
when viewed using phase contrast microscopy [16]. Due to
the insidious nature of inflammatory disease a midrange
activation concentration of 150 ng/ml of PMAwas chosen for
the model as this dose generated a significant increase in cell
activity alongsidemoderate increase inNOproductionwhich
can be associated with low grade inflammation.
For the toxicity study, we used the biologically active form
of the vitamin, methylcobalamin, because it can be used as a
coenzyme by the cell without conversion. Clinically relevant
doses were used in this study to reflect current treatment
regimes. The methylcobalamin did not show any significant
increase in cell activity (Figure 4(a)) or in NO production
(Figure 4(b)).These data confirm the lack of gastric epithelial
cell toxicity of methylcobalamin which was used up to
values five times greater than the upper limit of cobalamin
(5000 pg/ml). This high concentration and lack of toxicity
are supported by clinical trials in Japan, where patients
with peripheral neuropathy were treated with 25mg/day IV
methylcobalamin [20] over 10 days for five months. This is
2.5 × 1010 times greater than the recommended dose for
patients with PA who are given 1mg/ml every 8–12 weeks.
These high doses showed no adverse side effects to patients,
which is supported by our in vitro model. Similarly, high
concentrations of inactive cobalamin are used clinically to
treat cyanide poisoning at very high doses of 4-5 g repeated
over consecutive days [11]. Reported side effect were only as
a transient urticarial rash; therefore toxicity is minimal with
extremely high doses over the short term.
The in vitro model was developed to observe the impact
of the atrophic gastritis on the cells of the gastric epithelium,
as the action of the cells can be linked to the progression
and development of the disease. In this model inflamma-
tion was achieved by the addition of 150 ng/ml PMA. This
concentration was identified as it generated an increase in
NO production from the cell alongside cell morphology
alterations, both of which are proposed to reflect a change in
function of the cell associated with low grade inflammation,
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as identified clinically in patients suffering from autoimmune
conditions. To observe the effect of the different cobalamins,
clinically relevant doses were incubated with the model.
Change in morphology lends itself to a change in func-
tion; individual Caco-2 cells observed under inflamed condi-
tions in this model separated from the continuousmonolayer
associated with a fully functional gastric lining, therefore
losing cell-cell tight junctions as seen in normal culture. The
lack of continuous monolayer and loss of tight junctions
can themselves act as an inflammatory trigger exacerbating
the situation, potentially leading to chronic inflammation
associated with comorbid conditions such as gastric cancer.
Similarly ultrastructural alterations have also been implicated
in altered cell proliferation and cellular kinetics both of
which will impact the structure, function, and integrity of the
epithelial lining [22].
The cells in this model demonstrated the ability to return
to more typical morphology postinflammatory stimuli after
incubation with higher levels of cobalamin, giving a more
clinically reflective model of acute pathological conditions
characterised by excessive NO production in the intestine,
which leads to the increased permeability of cells, a potential
trigger of inflammatory disease [20].
Methylcobalamin showed no observable differences
towards the suppression of NO (Figure 5); however this may
have been masked by the increased cell activity observed
at higher concentrations in the presence of inflammatory
stimuli (Figure 5).
This could be due to the availability of the biologically
active form for inclusion into the normal cell processes of
DNAmethylation and theKrebs cycle as postulated [1]. Itmay
also be that the upregulation of these processes has prevented
the availability of themethylcobalamin for the purpose ofNO
inhibition. This implies a prioritisation of basic cell function
over its protective role. Despite the lack of observable NO
inhibition, morphological studies highlighted the return of
the cell morphology to be more reminiscent of the control
cells on the addition of the biologically active cobalamin in
the presence of the inflammatory stimuli.
By contrast the inactive hydroxocobalamin showed no
observable increase in cell activity (Figure 6(b)), combined
with a trend towards a reduction in the amount of freely
available NO under inflammatory stimuli. Indeed, there is a
significant difference between cells incubated with PMA and
hydroxocobalamin at 200 and 500 pg/ml and their respective
counterparts without PMA. The biologically inactive nature
of hydroxocobalamin may prevent its immediate uptake into
cellular processes as it needs to be converted to methyl-
cobalamin before it can be used by the cells [17], allowing
it to remain available for the “mopping” up of endogenous
NO. Cellular pretreatment with inactive cobalamin has been
noted in previous studies as preventing the process of apop-
tosis [23].
The reduction in NO concentration with the addition
of cobalamin was highlighted but not significant in these
studies; it is hypothesised that this is due to the mimicking of
a low grade inflammatory condition. Birch et al. [24] further
demonstrated the antioxidant potential of cobalamin con-
ferred by its ability to reduce NO concentrations. Similarly,
studies have also shown an increase in the transporter protein
transcobalamin in acute and chronic inflammatory states [11].
Methylcobalamin serves to reduce homocysteine to
methionine via methionine synthase, which alongside ATP
ensures the methylation of RNA, DNA, and proteins linked
with endothelial cell dysfunction and the formation of
reactive oxygen species (ROS) including NOS [11]. As a
result, patients with cobalamin deficiency possess a decreased
ability to inhibit NO alongside an increased NO production,
promoting a perpetual inflammatory state with systemic
clinical impact. Indeed, increased homocysteine levels are
associated with the induction of apoptosis in human bone
marrow stromal cells, human umbilical vein endothelial cells,
and endothelial progenitor cells; the apoptosis was shown to
be prevented by the pretreatment with inactive cobalamin
metabolism [21].
The concentration range of clinically acceptable plasma
cobalamin varies between countries. In the UK, patients
are considered borderline abnormal when the cobalamin
levels are between 120 and 180 pg/ml and below 120 pg/ml
is an abnormal result [12]. In Asian countries the lower
limit is 500 pg/ml [21]. This discrepancy means patients
who are considered normal in European countries would
be considered as having a low cobalamin elsewhere, and so
patients with cobalamin deficiency will be missing out on
treatment, leading to further deterioration of their condition
before diagnosis causing great distress for the patient. In this
study, low concentrations of cobalamin (200 pg/ml) benefit-
ted gastric epithelial cells in an inflammatory environment
by restoring some of the features of normal gastric cell
morphology; however the cells still remained fairly atypical in
shape and size. It can be argued that patients presenting with
symptoms and cobalamin levels less than 500 pg/ml should
receive cobalamin treatment as the levels in the bodymay not
be sufficient to reduce excessive inflammation. This would
move the UK lower limit of normal in line with that of Asia.
The recommended treatment of cobalamin deficiency
is not sufficient for a large number of patients [8]; its
symptoms are systemic as a result of the importance of
cobalamin in DNA replication and respiration. This study
demonstrated that PMA is a suitable inducer of low grade
gastric inflammation; it highlights that different forms of
cobalamin may be more suitable for treatment due to their
ability to be taken up with cellular processes. This work has
highlighted that levels below those currently administered
promote a beneficial cellular effect; overall more investigation
is needed to define to optimal treatment approach based
on cellular activity and health, not defined by the systemic
tolerance of healthy individuals.
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